- TREMFYA® sustained clinical, endoscopic, and histologic outcomes through Week 140 in ulcerative colitis.
- 80.8% of patients were in clinical remission at Week 140.
- 87.5% of patients in clinical remission at Week 44 maintained it through Week 140.
- No new safety concerns were observed during the study.
Study Overview
Johnson & Johnson announced long-term data from the QUASAR LTE study, demonstrating that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis (UC). These findings were presented at the European Crohn’s and Colitis Organisation (ECCO) 2026 conference.
Key Results
At Week 140, 80.8% of patients taking TREMFYA® were in clinical remission. Additionally, 78.6% achieved histo-endoscopic mucosal improvement (HEMI), and 53.6% were in endoscopic remission. Approximately 89% of eligible participants completed treatment through Week 140, with nearly all in clinical remission being corticosteroid-free for at least eight weeks.
Long-term Efficacy
The study showed that 87.5% of patients in clinical remission at Week 44 maintained it through Week 140. Efficacy was consistent regardless of prior biologic and/or JAK inhibitor treatment history, and no new safety concerns were identified.
Treatment Mechanism
TREMFYA® is a dual-acting monoclonal antibody that blocks IL-23 and binds to CD64, a receptor on cells producing IL-23, a cytokine involved in immune-mediated diseases. The findings are based on in vitro studies.
Regulatory Approvals
TREMFYA® has received FDA and European Commission approval for both subcutaneous (SC) and intravenous (IV) induction options for treating adults with moderately to severely active Crohn’s disease and ulcerative colitis. It is administered via an IV induction regimen, followed by SC maintenance.
